Every time global health agencies announce that Kenya, Uganda, and South Africa are gearing up to manufacture next-generation HIV prevention medications locally, the comment sections explode with applause. Philanthropists pop champagne. Journalists write glowing pieces about self-reliance and breaking free from overseas drugmakers.
It sounds wonderful on a PowerPoint slide. It feels like social justice.
It is also an expensive, feel-good delusion that avoids the actual bottleneck keeping lifesaving science away from the people who need it.
For decades, the lazy consensus in global public health has been that geographical proximity equals security. If a factory sits in Nairobi or Kampala instead of New Jersey or Mumbai, the logic goes, supply chains magically become resilient, sovereignty is achieved, and prices plummet.
This argument collapses under the weight of basic economic reality and regulatory physics.
The Factory Fallacy
Let us look at what is actually happening. Global health bodies like Unitaid are pouring resources into local manufacturers—such as Universal Corporation in Kenya, Quality Chemical Industries in Uganda, and Aspen Pharmacare in South Africa—to prep them for regional production of pipeline tools like the monthly oral preventative alimatravir or long-acting injectables.
The underlying premise is that African nations are hamstrung purely by a lack of local brick-and-mortar production lines.
That is false. Almost all active pharmaceutical ingredients are sourced externally, and setting up complex secondary or tertiary synthesis plants for advanced antiretrovirals requires massive, sustained capital expenditure, hyper-specialized workforces, and stringent quality assurance frameworks that routinely dwarf the local market margins.
Imagine a scenario where a local plant spends three years and tens of millions of dollars scaling up production for a novel preventative molecule, only for international patent holders or bio-equivalency shifts to render the formulation secondary before the first batch clears regulatory red tape. Who absorbs that loss? Not the funding agencies. The local economy does.
Local manufacturing does not automatically mean lower costs or greater availability. Often, it means protected, inefficient local monopolies that cannot compete on global economies of scale, resulting in higher unit costs than importing generics from established hubs in India or Egypt.
The Real Crisis Is Not Where Drugs Are Made
The obsession with manufacturing sovereign pride projects blinds everyone to the real emergency: distribution, structural underfunding, and political cowardice.
Look at what happened when foreign aid budgets were slashed. Thousands of clinics shuttered. Healthcare workers lost their jobs. Breakthrough interventions like lenacapavir—the twice-yearly injectable that changes the math of adherence—sit trapped behind rationing, bureaucratic friction, and severe funding gaps.
People are not missing out on revolutionary preventative options because Uganda isn't synthesizing the compound locally. They are missing out because health systems are cash-strapped, marginalized communities face state-sanctioned stigma, and procurement pipelines are starved of predictable financing.
Building a state-of-the-art production facility does not fix a broken primary healthcare clinic network. It just gives bureaucrats something shiny to cut a ribbon in front of while basic service delivery rots from the inside out.
What Actually Works
If we want to stop treating HIV like an eternal crisis management exercise, we need to abandon nationalistic manufacturing fantasies and focus on what moves needles.
- Aggressive procurement pooling: Stop pretending every country needs its own independent production line. Leverage collective buying power to force pharmaceutical giants into transparent, non-profit or low-margin pricing structures across the entire continent simultaneously.
- Streamline regulatory harmonization: The single biggest drag on medical access in Africa is not manufacturing capacity; it is the fractured, painfully slow cross-border regulatory approval process. If a drug is approved by a stringent authority, mutual recognition agreements should allow it to cross borders instantly without repeating years of redundant local bureaucracy.
- Invest in last-mile delivery mechanisms: Spend the money where the friction actually lives. Fund community-led distribution, peer-led delivery networks for key populations, and decentralized clinical touchpoints that bypass traditional, judgmental hospital gates entirely.
Sovereignty isn't measured by whether your own soil produced the vial. It is measured by whether your citizens can walk into a clinic down the street and walk out fully protected, free of charge, and free of judgment.
Stop funding vanity factories. Fix the delivery pipes.
